| Attribute |
Value |
| 52 Week Change |
-0.12162161 |
| Address1 |
828 Winter Street |
| Address2 |
Suite 300 |
| All Time High |
391.3 |
| All Time Low |
6.468 |
| Ask |
11.64 |
| Ask Size |
2 |
| Average Daily Volume10 Day |
57,220 |
| Average Daily Volume3 Month |
46,811 |
| Average Volume |
46,811 |
| Average Volume10Days |
57,220 |
| Beta |
-0.122 |
| Bid |
6.72 |
| Bid Size |
2 |
| Book Value |
7.785 |
| City |
Waltham |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
9.24 |
| Current Ratio |
3.59 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
9.32 |
| Day Low |
8.98 |
| Debt To Equity |
9.15 |
| Display Name |
Xilio Therapeutics |
| Earnings Timestamp End |
1,754,911,858 |
| Earnings Timestamp Start |
1,754,479,858 |
| Ebitda |
-40,855,000 |
| Ebitda Margins |
-0.76387 |
| Enterprise To Ebitda |
2.164 |
| Enterprise To Revenue |
-1.653 |
| Enterprise Value |
-88,413,568 |
| Eps Forward |
-0.58 |
| Eps Trailing Twelve Months |
-2.28 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
8.4406 |
| Fifty Day Average Change |
0.7993994 |
| Fifty Day Average Change Percent |
0.09470883 |
| Fifty Two Week Change Percent |
-12.162161 |
| Fifty Two Week High |
12.74 |
| Fifty Two Week High Change |
-3.5 |
| Fifty Two Week High Change Percent |
-0.2747253 |
| Fifty Two Week Low |
6.468 |
| Fifty Two Week Low Change |
2.7719998 |
| Fifty Two Week Low Change Percent |
0.4285714 |
| Fifty Two Week Range |
6.468 - 12.74 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,634,909,400,000 |
| Float Shares |
3,752,078 |
| Forward Eps |
-0.58 |
| Forward P E |
-15.931034 |
| Free Cashflow |
-23,032,876 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
76 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.79128 |
| Gross Profits |
42,321,000 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.28576002 |
| Held Percent Institutions |
0.51838 |
| Implied Shares Outstanding |
6,575,139 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,021-10-22 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,773,619,200 |
| Last Split Factor |
1:14 |
| Long Business Summary |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. |
| Long Name |
Xilio Therapeutics, Inc. |
| Market |
us_market |
| Market Cap |
60,754,284 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_365333564 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-31,300,000 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
59,833,764 |
| Number Of Analyst Opinions |
1 |
| Open |
9.1 |
| Operating Cashflow |
-56,313,000 |
| Operating Margins |
-1.11575 |
| Payout Ratio |
0.0 |
| Phone |
857 524 2466 |
| Previous Close |
9.15 |
| Price Hint |
2 |
| Price To Book |
1.1868979 |
| Price To Sales Trailing12 Months |
1.1359338 |
| Profit Margins |
-0.58522 |
| Quick Ratio |
3.499 |
| Quote Type |
EQUITY |
| Recommendation Key |
none |
| Region |
US |
| Regular Market Change |
0.0900002 |
| Regular Market Change Percent |
0.983608 |
| Regular Market Day High |
9.32 |
| Regular Market Day Low |
8.98 |
| Regular Market Day Range |
8.98 - 9.32 |
| Regular Market Open |
9.1 |
| Regular Market Previous Close |
9.15 |
| Regular Market Price |
9.24 |
| Regular Market Time |
1,783,972,800 |
| Regular Market Volume |
71,378 |
| Return On Assets |
-0.19761999 |
| Return On Equity |
-0.752 |
| Revenue Growth |
3.317 |
| Revenue Per Share |
9.249 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
6,575,139 |
| Shares Percent Shares Out |
0.026600001 |
| Shares Short |
174,619 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
165,274 |
| Short Name |
Xilio Therapeutics, Inc. |
| Short Percent Of Float |
0.0297 |
| Short Ratio |
4.84 |
| Source Interval |
15 |
| State |
MA |
| Symbol |
XLO |
| Target High Price |
20.0 |
| Target Low Price |
20.0 |
| Target Mean Price |
20.0 |
| Target Median Price |
20.0 |
| Total Cash |
150,332,992 |
| Total Cash Per Share |
25.127 |
| Total Debt |
6,638,000 |
| Total Revenue |
53,484,000 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-2.28 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
9.108125 |
| Two Hundred Day Average Change |
0.13187504 |
| Two Hundred Day Average Change Percent |
0.014478835 |
| Type Disp |
Equity |
| Volume |
71,378 |
| Website |
https://xiliotx.com |
| Zip |
2,451 |